AI Verdict
ICCC has stronger fundamentals based on our AI analysis.
ICCC vs IBRX Fundamental Comparison
| Metric | ICCC | IBRX |
|---|---|---|
| Revenue | $27.6M | $113.3M |
| Net Income | $-1.0M | $-351.4M |
| Net Margin | -3.8% | -310.2% |
| ROE | -3.8% | N/A |
| ROA | -2.4% | -70.0% |
| Current Ratio | 4.26x | 5.10x |
| Debt/Equity | 0.34x | N/A |
| EPS | $-0.12 | $-0.38 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
ICCC vs IBRX: Frequently Asked Questions
Is ICCC or IBRX a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), ICCC has stronger fundamentals. ICCC is rated HOLD (72% confidence) while IBRX is rated STRONG SELL (92% confidence). This is not investment advice.
How does ICCC compare to IBRX fundamentally?
IMMUCELL CORP /DE/ has ROE of -3.8% vs ImmunityBio, Inc.'s N/A. Net margins are -3.8% vs -310.2% respectively.
Which stock pays higher dividends, ICCC or IBRX?
ICCC has a dividend yield of N/A or no dividend while IBRX has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in ICCC or IBRX for long term?
For long-term investing, consider that ICCC has HOLD rating with 72% confidence, while IBRX has STRONG SELL rating with 92% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about ICCC vs IBRX?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For ICCC vs IBRX, the AI consensus favors ICCC based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.